To assess the effect of combined Ddx41 and Trp53 heterozygosity on the development of hematologic disease, we transplanted CD45.2+ Ddx41+/f;Trp53+/−;RosaCreERT2 BM cells into lethally-irradiated CD45.1+ recipients without competitor cells, excised the Ddx41-floxed allele by tamoxifen treatment, and then followed the recipient mice for up to one year. This evidence concerns the gene TP53 and hematologic disorder.